UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
GreenLight Biosciences Holdings, PBC
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
39536G 105
(CUSIP Number)
Meg Lane
120 S. Central Avenue, Suite 1000
St. Louis, MO 63105
(314) 392-5259
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
May 29, 2023
(Date of Event which Requires Filing of this
Statement)
If the filing person has previously filed
a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of
Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨
Note:
Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Section 240.13d-7
for other parties to whom copies are to be sent.
* |
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. |
The information required on the remainder of this cover page shall
not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
1 |
NAMES OF REPORTING PERSONS |
|
|
Lewis & Clark Ventures I, LP |
|
|
|
|
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
(a) |
¨ |
|
(b) |
x |
|
|
3 |
SEC USE ONLY |
|
|
|
|
|
|
|
4 |
SOURCE OF FUNDS (SEE INSTRUCTIONS) |
|
|
WC |
|
|
|
|
5 |
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E) |
|
¨ |
|
|
|
|
|
6 |
CITIZENSHIP OR PLACE OF ORGANIZATION |
|
|
Delaware |
|
|
|
|
NUMBER OF SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING PERSON
WITH |
7 |
SOLE VOTING POWER |
|
|
557,632 |
|
|
|
|
8 |
SHARED VOTING POWER |
|
|
|
|
|
|
|
9 |
SOLE DISPOSITIVE POWER |
|
|
557,632 |
|
|
|
|
10 |
SHARED DISPOSITIVE POWER |
|
|
|
|
|
|
|
11 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
|
|
557,632 |
|
|
|
|
12 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) |
|
¨ |
|
|
|
|
|
13 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) |
|
|
0.37% (1) |
|
|
|
|
14 |
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) |
|
|
OO |
|
|
|
|
(1) |
Calculated based on the 151,681,314 shares of the Common Stock, par value $0.0001 per share (the “Common Stock”) of GreenLight Biosciences Holdings, PBC (the “Issuer” or the “Company”) outstanding as of May 8, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on May 11, 2023 (the “Form 10-Q”). |
1 |
NAMES OF REPORTING PERSONS |
|
|
Lewis & Clark Plant Sciences Fund I, LP |
|
|
|
|
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
(a) |
¨ |
|
(b) |
x |
|
|
3 |
SEC USE ONLY |
|
|
|
|
|
|
|
4 |
SOURCE OF FUNDS (SEE INSTRUCTIONS) |
|
|
WC |
|
|
|
|
5 |
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E) |
|
¨ |
|
|
|
|
|
6 |
CITIZENSHIP OR PLACE OF ORGANIZATION |
|
|
Delaware |
|
|
|
|
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
7 |
SOLE VOTING POWER |
|
|
1,816,746 |
|
|
|
|
8 |
SHARED VOTING POWER |
|
|
|
|
|
|
|
9 |
SOLE DISPOSITIVE POWER |
|
|
1,816,7463 |
|
|
|
|
10 |
SHARED DISPOSITIVE POWER |
|
|
|
|
|
|
|
11 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
|
|
1,816,746 |
|
|
|
|
12 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) |
|
¨ |
|
|
|
|
|
13 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) |
|
|
1.20% (1) |
|
|
|
|
14 |
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) |
|
|
OO |
|
|
|
|
(1) |
Calculated based on the 151,681,314 shares of the Common Stock of the Issuer outstanding as of May 8, 2023, as reported in the Form 10-Q. |
Item 1. Security and Issuer
This statement on Schedule 13D relates to the
Reporting Persons’ (as defined in Item 2 below) beneficial ownership interest in the common stock, par value $0.0001 per share (the
“Common Stock”), of GreenLight Biosciences Holdings, PBC, a Delaware corporation (the “Issuer” or the “Company”).
The address of the principal executive office of the Issuer is 29 Hartwell Avenue, Lexington, MA 02421. Information given in response
to each item shall be deemed incorporated by reference in all other items, as applicable.
Item 2. Identity and Background.
(a) |
This Schedule 13D is being jointly filed by (1) Lewis & Clark Ventures I, LP and (2) Lewis & Clark Plant Sciences Fund I, LP (each a “Reporting Person” and collectively, the “Reporting Persons”), with respect to Common Stock beneficially owned by the Reporting Persons. The joint filing agreement of the Reporting Persons is attached hereto as Exhibit 99.4. |
(b) |
The principal business address of the Reporting Persons is 120 S. Central Avenue, Suite 1000, St. Louis, MO 63105. |
(c) |
The principal business of the Reporting Persons is to invest in the securities of a variety of companies. |
(d) |
During the last five years, none of the Reporting Persons has been convicted in a criminal proceeding of the type specified in Item 2(d) of Schedule 13D. |
(e) |
During the last five years, none of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. |
Item 3. Source and Amount of Funds or Other Consideration.
The description of the Merger Agreement (as defined
below), the Note Purchase Agreement (as defined below) and the Contribution and Exchange Agreements (as defined below) included below
in response to Item 4 are incorporated by reference in this Item 3.
Item 4. Purpose of Transaction.
The Reporting Persons’ response to Item
3 is incorporated by reference into this Item 4
Merger Agreement
On May 29, 2023, the
Issuer entered into that certain Agreement and Plan of Merger (the “Merger Agreement”) with SW ParentCo, Inc., a Delaware
corporation (“Parent”) and wholly-owned subsidiary of Fall Line Endurance Fund, LP, and SW MergerCo, Inc., a Delaware
corporation and a wholly owned subsidiary of Parent (“Merger Sub”). Pursuant to the Merger Agreement, and subject to the terms
and conditions thereof, (a) Merger Sub will commence a tender offer (the “Offer”) to purchase any and all of the outstanding
shares of Common Stock, other than shares of Common Stock held by the certain stockholders of the Company that have entered into the Contribution
and Exchange Agreements whereby they have agreed to contribute to Parent their shares of Common Stock (such shares of Common Stock, collectively,
the “Rollover Shares”, and such shareholders of the Company holding Rollover Shares, collectively, the “Rollover Stockholders”,
each a “Rollover Stockholder”) and the shares of Common Stock held by Parent and Merger Sub and certain other shares specified
in the Merger Agreement (together with the Rollover Shares, the “Excluded Shares”), at a purchase price of US$0.30 per share
of Common Stock (the “Offer Price”), (b) immediately following the consummation of the Offer, each of the Rollover Stockholders
will contribute their Rollover Shares to Parent (the “Rollover”) and (c) as soon as practicable following the consummation
of the Merger, but following the consummation of the Rollover, Merger Sub will be merged with and into the Issuer, with the Issuer continuing
as the surviving corporation (the “Surviving Corporation”) and becoming a wholly owned subsidiary of Parent (the “Merger”).
Under the terms of the Merger
Agreement, at the effective time of the Merger (the “Effective Time”), each share of Common Stock issued and outstanding immediately
prior to the Effective Time, other than the Excluded Shares, will be cancelled and converted into the right to receive the Offer Price
in cash per share without interest and net of any applicable withholding taxes. The Excluded Shares will be automatically cancelled and
cease to exist, without payment of any consideration or distribution therefor.
Immediately prior to the Effective
Time, each option to purchase shares of Common Stock (each, a “Company Option”), whether vested or unvested, that is outstanding
and unexercised immediately prior to the Effective Time and has a per share exercise price less than the Offer Price (an “In-The-Money
Option”) shall be cancelled in exchange for an amount in cash equal to the number of shares of Company Common Stock subject to such
Company Option multiplied by the amount by which (x) the Offer Price exceeds (y) the per share exercise price for such an In-the-Money
Option (the “Company Option Cash Out Amount”). Each Company option that is not an In-The-Money Option shall be cancelled at
the effective time without payment. Each outstanding restricted stock unit award subject to time-based or other vesting restrictions (each,
a “Company RSU Award”) immediately prior to the Effective Time, shall, to the extent not vested, become fully vested and then
(ii) each such Company RSU Award shall be automatically canceled in consideration for the right to receive a lump sum cash payment
equal to the product of (x) the Offer Price and (y) the number of shares of Common Stock represented by such Company RSU Award
(the “Company RSU Cash Out Amount”). Payment of the Company Option Cash Out Amount and the Company RSU Cash Out Amount shall
be made no later than thirty (30) business days following the Closing, subject to any applicable withholding taxes.
In addition, the Company shall
promptly take all necessary actions to ensure that no offering or purchase period commences under the Company’s 2022 Employee Stock
Purchase Plan (the “Company ESPP”) and that no shares of capital stock of the Company are issued under the Company ESPP. Prior
to the Effective Time, the Company shall take all necessary actions to terminate the Company ESPP.
At the Effective Time, each
outstanding warrant to purchase shares of Common Stock pursuant to the Warrant Agreement, dated January 13, 2021, by and between
Environmental Impact Acquisition Corp. and Continental Stock Transfer & Trust Company (the “Warrant Agreement”) will,
in accordance with its terms, automatically and without any required action on the part of the holder thereof, become a warrant exercisable
for the Offer Price that such holder would have received if such warrant had been exercised immediately prior to the Effective Time; provided
that if a holder of such warrant properly exercises such warrant within thirty (30) days following the public disclosure of the consummation
of the Merger, the holder of such warrant will be entitled to the Black-Scholes Warrant Value (as defined in the Warrant Agreement) with
respect to such warrant, which would have been equal to approximately $0.00065873 per warrant as of the close of trading on May 26,
2023.
The Merger Agreement contains
customary representations and warranties from the parties, and each party has agreed to customary covenants, including, among others,
covenants relating to (i) the conduct of business of the Company during the interim period between the execution of the Merger Agreement
and the Effective Time (including prohibition on certain actions, such as amendment to organizational documents, payment of dividends
or distributions, incurrence of certain capital expenditures, entry into a new line of business, and incurrence of certain indebtedness,
among others) and (ii) the obligation to use commercially reasonable efforts to obtain consents, approvals, registrations, waivers,
permits, orders or other authorizations from, and making any filings and notifications with, any governmental authority or third party
necessary, property or advisable under applicable law to consummation the Offer and the Merger.
The Offer will initially remain
open for 20 business days (as calculated in accordance with Rule 14d-1(g)(3) under the Securities Exchange Act of 1934, as amended)
from (and including) the date of commencement of the Offer. If at the scheduled expiration time of the Offer, any condition to the Offer
(other than any conditions that by their nature are to be satisfied at the expiration of the Offer, but subject to such conditions remaining
capable of being satisfied) has not been satisfied and has not been waived by Parent or Merger Sub (to the extent waivable), Merger Sub
may, in its discretion, and Parent may cause Merger Sub to, extend the Offer in accordance with the terms of the Merger Agreement to permit
the satisfaction of all Offer conditions. The obligation of Merger Sub to consummate the Offer is subject to the satisfaction or waiver
of conditions, including, among others, there being a number of shares of Company Common Stock validly tendered (and not properly withdrawn)
prior to the expiration of the Offer (but excluding shares tendered pursuant to guaranteed delivery procedures that have not yet been
“received” by the “depository,” as such terms are defined in section 251(h)(6) of the Delaware General Corporate
Law (the “DGCL”)), together with any shares of Company Common Stock otherwise owned by Merger Sub or its “affiliates”
(as defined in section 251(h)(6) of the DGCL) that do not represent at least (a) a majority of the outstanding Company Common
Stock, not otherwise owned by Merger Sub, its “affiliates” (as defined in section 251(h)(6) of the DGCL) or the Rollover
Stockholders, (as defined below) and (b) the number of the shares of Company Common Stock outstanding immediately following the consummation
of the Offer that, together with the shares of Company Common Stock owned by Merger Sub, its “affiliates” (as defined in section
251(h)(6) of the DGCL) and the Rollover Stockholders, equals at least such percentage of the shares of Company Common Stock, and
of each class or series thereof, that would be required to adopt the Merger Agreement under the DGCL and the Company’s organizational
documents.
The Merger Agreement provides
for a 30-day “go-shop” period beginning on the date of the Merger Agreement and continuing until 11:59 p.m. (New York
City time) on June 28, 2023, during which period the Company and its representatives are permitted to actively initiate, solicit,
knowingly facilitate or encourage alternative acquisition proposals from third parties and to provide information to, and participate
in discussions and engage in negotiations with, third parties regarding any alternative acquisition proposals. After such 30-day go-shop
period and subject to certain exceptions, the Company will be subject to a customary “no-shop” provision whereby it is prohibited
from (i) entering into solicitations, discussions or negotiations concerning, or providing confidential information in connection
with, any alternative transaction and (ii) withholding, withdrawing, qualifying, amending or modifying the Company Recommendation
in a manner adverse to Parent.
The “no shop”
provision allows the Company, under certain circumstances and in compliance with certain obligations set forth in the Merger Agreement,
to provide non-public information and engage in discussions and negotiations with respect to an unsolicited acquisition proposal that
constitutes or is reasonably expected to lead to an alternative transaction that the Board (as defined below) (or an authorized committee
thereof, including the Special Committee (as defined below)) determines would be more favorable, from a financial point of view, to the
Company’s stockholders than the Merger and in the best interests of those materially affected by the Company’s conduct (a
“Superior Proposal”).
Under certain circumstances
and in compliance with certain obligations set forth in the Merger Agreement, the Company is permitted to terminate the Merger Agreement
prior to the Acceptance Time (as defined in the Merger Agreement) to accept a Superior Proposal, subject to the payment of an expense
reimbursement. The Company is also required to pay an expense reimbursement (A) if Parent terminates because (i) the board of
directors of the Company (the “Board”), acting on the recommendation of the Special Committee of the Board (the “Special
Committee”), shall have effected an Adverse Recommendation Change (as defined in the Merger Agreement); provided, that Parent must
provide notice of termination within five (5) business days of the Adverse Recommendation Change, (ii) the Company materially
breaches Section 5.3 of the Merger Agreement, (iii) the
Company fails to recommend
against a competing tender or exchange offer within ten (10) business days thereof, (iv) the Company fails to publicly affirm
the Company Recommendation in favor of the Offer within ten (10) business days of a request from Parent (when permitted to make such
a request under the Merger Agreement), or (v) the Acceptance Time has not occurred by February 29, 2024 (or as extended in accordance
with the Merger Agreement) if as of such time Parent could have terminated the Merger Agreement pursuant to any of clauses (i) through
(iv) immediately above or (B) if, following the date of the Merger Agreement, (i) an alternative acquisition proposal is
publicly announced and has not been withdrawn prior to termination of the Merger Agreement, (ii) (x) Parent terminates the Merger
Agreement because the Company breaches any of its representations or warranties, or fails to perform any of its covenants or agreements
contained in the Merger Agreement, in any such case, which gives rise to the failure of certain offer conditions in the Merger Agreement
(and such breach is not cured within 20 business days thereof or is not capable of being cured), or (y) either party terminates the
Merger Agreement because the Offer has expired as a result of the non-satisfaction of one or more offer conditions or has been terminated
or withdrawn and (iii) within 12 months after termination, the Company consummates any alternative transaction or enters into a definitive
agreement providing for an alternative transaction. In no event would the Company be required to pay an expense reimbursement fee on more
than one occasion. The Company’s expense reimbursement obligation cannot exceed $1,575,000.
If the Acceptance Time occurs,
the Company must reimburse Parent for all of its fees and expenses relating to the Merger Agreement, the Note Purchase Agreement, the
Contribution and Exchange Agreements and the transactions contemplated thereby, including the Offer and the Merger, without any cap.
If the Merger is effected,
the Issuer’s Common Stock will be delisted from the NASDAQ Capital Market and the Issuer’s obligation to file periodic reports
under the Act will terminate, and the Issuer will be privately held.
Note Purchase Agreement
Concurrently with the execution of the Merger
Agreement, each of the persons named under column (A) below (i) entered into those certain Secured Convertible Note Purchase
Agreement (the “Note Purchase Agreements”) with Parent confirming its commitment to pay to Parent, at the Acceptance Time
(as defined in the Merger Agreement) cash in the amount set forth opposite such person(s)’s name(s) under column (B) (less
the amount under column (C)) in exchange for secured convertible promissory notes and (ii) were issued by the Issuer Advance Notes
(the “Advance Notes”) and made a cash payment to the Issuer in the amount set forth in column (C) (each a “Note”,
and collectively the “Notes”) for purposes of funding (a) the Offer Price in the Offer and in the Merger, (b) fees
and expenses incurred by the parties to the Merger Agreement in connection with the transactions contemplated thereby and (c) general
working capital of the Issuer, prior to the consummation of the Merger, and of Parent, including the Surviving Corporation, following
the consummation of the Merger.
(A) Name | |
(B) Aggregate Investment Amount | | |
(C) Advance Note Commitment Amount | |
Fall Line Endurance Fund, L.P. | |
$ | 10,000,000.00 | | |
$ | 2,880,460.87 | |
S2G Builders Food & Agriculture Fund III, LP | |
$ | 10,000,000.00 | | |
$ | 2,880,460.87 | |
MVIL, LLC | |
$ | 10,000,000.00 | | |
$ | 2,880,460.87 | |
Cormorant Private Healthcare Fund II, LP | |
$ | 4,829,000.00 | | |
$ | 1,390,974.56 | |
Cormorant Global Healthcare Master Fund, LP | |
$ | 5,171,000.00 | | |
$ | 1,489,486.32 | |
Macro Continental, Inc. | |
$ | 5,000,000.00 | | |
$ | 1,440,230.44 | |
Series GreenLight 3, a separate series of BlueIO Growth LLC | |
$ | 6,075,000.00 | | |
$ | 1,749,879.98 | |
Furneaux Capital Holdco, LLC | |
$ | 200,000.00 | | |
$ | 57,609.22 | |
Velocity Financial Group, LLC | |
$ | 300,000.00 | | |
$ | 86,413.83 | |
Lewis & Clark Ventures I, LP | |
$ | 500,000.00 | | |
$ | 144,023.04 | |
Total | |
$ | 52,075,000.00 | | |
$ | 15,000,000.00 | |
Contribution and Exchange Agreement
In connection with the transactions
contemplated by the Merger Agreement, Parent entered into with each of the Rollover Stockholders, a Contribution and Exchange Agreement
(collectively, the “Contribution and Exchange Agreements”) pursuant to which the Rollover Stockholders agreed to contribute
an aggregate 120,521,038 Rollover Shares to Parent, in exchange for shares of Series A-2 Preferred Stock, par value $0.001 per share,
of Parent. Such Rollover Shares constitute approximately 79.46% of the total issued and outstanding shares of Company Common Stock as
of the date hereof. The Contribution and Exchange Agreements will terminate upon the first to occur of the consummation of the Merger,
the date and time that the Merger Agreement is terminated in accordance with its terms and the date and time that the Board or the Special
Committee make an Adverse Recommendation Change in accordance with the Merger Agreement.
The foregoing descriptions
of the Merger Agreement, the Note Purchase Agreement, and the Contribution and Exchange Agreements and the transactions contemplated thereby
do not purport to be complete and are qualified in their entirety by reference to the full text of the Merger Agreement, a copy of which
is filed as Exhibit 99.1 to this Schedule 13D, the Note Purchase Agreement, a copy of which is filed as Exhibit 99.2 to this
Schedule 13D, and the Contribution and Exchange Agreement, a copy of which is filed as Exhibit 99.3 to this Schedule 13D, each of
which is incorporated by reference into this Item 4. The Merger Agreement, the Note Purchase Agreement, and the Contribution and Exchange
Agreements are incorporated herein by reference to provide investors and security holders with information regarding its terms. It is
not intended to provide any other factual or financial information about the Issuer, Parent, or any of their respective subsidiaries or
affiliates. The representations, warranties and covenants contained in the Merger Agreement, the Note Purchase Agreement, and the Contribution
and Exchange Agreements were made only for purposes of that agreement, as applicable, and as of specific dates; were solely for the benefit
of the other parties thereto; may be subject to limitations agreed upon by the parties, including being qualified by confidential disclosures
made for the purposes of allocating contractual risk between the parties thereto instead of establishing those matters as facts; and may
be subject to standards of materiality applicable to the contracting parties that differ from those applicable to investors. Investors
should not rely on the representations, warranties and covenants or any description thereof as characterizations of the actual state of
facts or condition of the Issuer, Parent, Merger Sub or any of their respective subsidiaries or affiliates. Moreover, information concerning
the subject matter of the representations, warranties and covenants may change after the date of such agreements, which subsequent information
may or may not be fully reflected in public disclosures by the Issuer or Parent. Neither Merger Agreement, the Note Purchase Agreement,
nor the Contribution and Exchange Agreements should not be read alone, but should instead be read in conjunction with the other information
regarding the companies and the transactions contemplated thereby that will be contained in, or incorporated by reference into, the tender
offer statement on Schedule TO and Schedule 13E-3 and the Solicitation/Recommendation Statement on Schedule 14D-9, as well as in the other
filings that each of the Issuer, Parent and Merger Sub make with the SEC.
III. Item 5. Interest in Securities of
the Issuer.
As a result of the Reporting Persons’ actions
in respect of the Contribution and Exchange Agreement, each Reporting Person may be deemed to be member of a “group” within
the meaning of Section 13(d)(3) of the Exchange Act. Such “group” may constitute the following individuals:
Name | |
Number of Shares | | |
% Ownership(1) | |
S2G Ventures Fund I, LP | |
| 2,087,043 | | |
| 1.38 | % |
S2G Ventures Fund II, LP | |
| 8,582,284 | | |
| 5.66 | % |
S2G Builders Food & Agriculture Fund III, LP | |
| 11,551,245 | | |
| 7.62 | % |
Builders GRNA Holdings, LLC | |
| 127,551 | | |
| 0.08 | % |
Morningside Venture Investments Ltd. | |
| 15,919,155 | | |
| 10.50 | % |
MVIL, LLC (morningside) | |
| 1,000,000 | | |
| 0.66 | % |
Fall Line Endurance Fund, LP | |
| 11,452,834 | | |
| 7.55 | % |
Kodiak Venture Partners III, L.P | |
| 9,573,157 | | |
| 6.31 | % |
Kodiak III Entrepreneurs Fund, L.P. | |
| 236,741 | | |
| 0.16 | % |
Continental Grain Company | |
| 2,387,044 | | |
| 1.57 | % |
Conti Greenlight Investors, LP | |
| 4,102,198 | | |
| 2.70 | % |
MLS Capital Fund II, L.P. | |
| 5,818,575 | | |
| 3.84 | % |
Cormorant Global Healthcare Master Fund, LP | |
| 4,751,020 | | |
| 3.13 | % |
Cormorant Private Healthcare Fund II, LP | |
| 4,437,639 | | |
| 2.93 | % |
Neglected Climate Opportunities, LLC | |
| 4,041,280 | | |
| 2.66 | % |
Rivas Ventures LLC | |
| 3,515,333 | | |
| 2.32 | % |
Prelude Ventures LC | |
| 3,189,151 | | |
| 2.10 | % |
CG Investments Inc. VI | |
| 1,552,500 | | |
| 1.02 | % |
Lewis & Clark Plant Sciences Fund I, LP | |
| 1,816,746 | | |
| 1.20 | % |
Lewis & Clark Ventures I, LP | |
| 557,632 | | |
| 0.37 | % |
Insud Pharma, S.L. | |
| 2,551,020 | | |
| 1.68 | % |
Xeraya Cove Ltd. | |
| 1,734,277 | | |
| 1.14 | % |
The Board of Trustees of the LeLand Stanford Junior University | |
| 1,687,374 | | |
| 1.11 | % |
Alexandria Venture Investments, LLC | |
| 1,609,909 | | |
| 1.06 | % |
Boscolo Intervest Limited | |
| 1,520,408 | | |
| 1.00 | % |
Macro Continental, Inc. | |
| 1,416,895 | | |
| 0.93 | % |
Malacca Jitra PTE Inc. | |
| 1,368,301 | | |
| 0.90 | % |
Cummings Foundation, Inc. | |
| 1,275,510 | | |
| 0.84 | % |
Grupo Ferrer Internacional, S.A. | |
| 1,094,248 | | |
| 0.72 | % |
Sage Hill Investors | |
| 1,000,000 | | |
| 0.66 | % |
Serum Institute | |
| 1,000,000 | | |
| 0.66 | % |
Tao Invest III LLC | |
| 834,817 | | |
| 0.55 | % |
Tao Invest V | |
| 1,836,847 | | |
| 1.21 | % |
Series GreenLight 2, a separate series of BlueIO Growth LLC | |
| 569,423 | | |
| 0.38 | % |
Series GreenLight, a separate series of BlueIO Growth LLC | |
| 500,890 | | |
| 0.33 | % |
New Stuff LLC | |
| 500,000 | | |
| 0.33 | % |
New Stuff Deux LLC | |
| 306,112 | | |
| 0.20 | % |
Lupa Investment Holdings, LP | |
| 367,369 | | |
| 0.24 | % |
RPB Ventures, LLC | |
| 300,000 | | |
| 0.20 | % |
Velocity Financial Group, LLC | |
| 292,186 | | |
| 0.19 | % |
David Brewster | |
| 172,500 | | |
| 0.11 | % |
Rosemary Sagar | |
| 208,704 | | |
| 0.14 | % |
Michael Ruettgers Revocable Trust as amended and restated | |
| 206,629 | | |
| 0.14 | % |
Furneaux Capital Holdco, LLC | |
| 188,134 | | |
| 0.12 | % |
Deval Patrick | |
| 172,500 | | |
| 0.11 | % |
Samambaia Investments Limited | |
| 159,493 | | |
| 0.11 | % |
Carole S. Furneaux | |
| 150,000 | | |
| 0.10 | % |
Alfa Holdings, Inc. | |
| 100,000 | | |
| 0.07 | % |
Ricardo Sagrera | |
| 93,860 | | |
| 0.06 | % |
Michael Steinberg | |
| 91,842 | | |
| 0.06 | % |
Rodrigo Aguilar | |
| 85,330 | | |
| 0.06 | % |
Roger Richard | |
| 69,888 | | |
| 0.05 | % |
Matthew Walker | |
| 63,775 | | |
| 0.04 | % |
Dennis Clarke | |
| 25,510 | | |
| 0.02 | % |
Eric Anderson | |
| 25,510 | | |
| 0.02 | % |
Karthikeyan Ramachandriya | |
| 47,000 | | |
| 0.03 | % |
Marta Ortega-Valle | |
| 29,798 | | |
| 0.02 | % |
Himanshu Dhamankar | |
| 27,255 | | |
| 0.02 | % |
Sweta Gupta | |
| 2,329 | | |
| 0.00 | % |
Jason Gillian | |
| 28,732 | | |
| 0.02 | % |
Ifeyinwa Iwuchukwu | |
| 14,886 | | |
| 0.01 | % |
Nicholas Skizim | |
| 26,965 | | |
| 0.02 | % |
Lorenzo Aulisa | |
| 2,697 | | |
| 0.00 | % |
Caitlin Macadino | |
| 28,821 | | |
| 0.02 | % |
Riverroad Capital Partners | |
| 12,010 | | |
| 0.01 | % |
Anna Senczuk | |
| 9,984 | | |
| 0.01 | % |
Steve Naugler | |
| 8,157 | | |
| 0.01 | % |
Maria Lurantos | |
| 4,015 | | |
| 0.00 | % |
TOTAL | |
| 120,521,038 | | |
| 79.46 | % |
(1) |
The ownership percentage below is based on the 151,681,314
shares of Common Stock outstanding as of May 8, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q. |
As a result, the group may be deemed to have acquired
beneficial ownership of all the shares beneficially owned by each member of the “group”. As such, the group may be deemed
to beneficially own in the aggregate 120,521,038 shares of Common Stock. The above Common Stock does not include any Common Stock
which may be beneficially owned by any of the other parties to the Merger Documents not listed above. The individuals and/or entities
listed in the table in this Item 5 other than the Reporting Persons herein have been notified that such individuals and/or entities may
beneficially own certain Common Stock and need to file separate beneficial ownership reports with the SEC related thereto. Neither the
filing of this Schedule 13D nor any of its contents, however, shall be deemed to constitute an admission by each Reporting Person that
it is the beneficial owner of any of the Common Stock beneficially owned in the aggregate by other members of the “group”
and their respective affiliates for purposes of Section 13(d) of the Act or for any other purpose, and such beneficial ownership
is expressly disclaimed.
The information disclosed under Item 4 above is hereby incorporated
by reference into this Item 5.
Item 6. Contracts, Arrangements, Understandings or Relationships
With Respect to Securities of the Issuer.
Item 4 above summarizes certain provisions of
the Merger Agreement, the Note Purchase Agreement and the Contribution and Exchange Agreements and is incorporated herein by reference.
A copy of each of the Merger Agreement, the Note Purchase Agreement, and the Contribution and Exchange Agreements is attached as an exhibit
to this Schedule 13D and each is incorporated herein by reference.
Except as set forth herein, the none of the Reporting
Persons has any contracts, arrangements, understandings or relationships (legal or otherwise) with any person with respect to any securities
of the Issuer, including but not limited to any contracts, arrangements, understandings or relationships concerning the transfer or voting
of such securities, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of
profits or losses, or the giving or withholding of proxies.
Item 7. Material to be Filed as Exhibits.
Exhibit 99.1: |
|
Agreement
and Plan of Merger, dated May 29, 2023, by and among Issuer, Parent and Merger Sub |
|
|
|
Exhibit 99.2: |
|
Secured
Convertible Note Purchase Agreement, dated May 29, 2023, by and among Parent and the investor signatories thereto. |
|
|
Exhibit 99.3 |
|
Form of
Contribution and Exchange Agreement, dated May 29, 2023, by and among each of the Rollover Stockholders and Parent |
|
|
|
Exhibit 99.4 |
|
Joint
Filing Agreement |
Schedules omitted pursuant to Item 601(a)(5) of Regulation S-K.
The Company agrees to furnish supplementally a copy of any omitted schedule to the SEC upon request; provided, however, that the Company
may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any schedules or
exhibits so furnished.
SIGNATURE
After reasonable inquiry and to the best of my
knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: June 8, 2023 |
LEWIS &
CLARK VENTURES I, LP |
|
|
|
By: |
/s/ Thomas Hillman |
|
Name:
|
Thomas
Hillman |
|
Title:
|
Managing
Partner |
|
|
Date: June 8, 2023 |
LEWIS &
CLARK PLANT SCIENCES FUND I, LP |
|
|
|
By: |
/s/
Larry Page |
|
Name:
|
Larry
Page |
|
Title:
|
Managing
Director |
Environmental Impact Acq... (NASDAQ:ENVIU)
과거 데이터 주식 차트
부터 8월(8) 2024 으로 9월(9) 2024
Environmental Impact Acq... (NASDAQ:ENVIU)
과거 데이터 주식 차트
부터 9월(9) 2023 으로 9월(9) 2024